Pfizer May Enjoy Blockbuster Cardiomyopathy Success With Tafamidis
Although tafamidis has been stalled at FDA for transthyretin-mediated polyneuropathy, Pfizer may have found a different path toward US approval with cardiovascular outcomes data in cardiomyopathy.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Unveiling its Phase III data showing both an all-cause mortality and cardiovascular hospitalization benefit, Pfizer thinks it can bring dramatic improvement in therapy for transthyretin cardiomyopathy.
Emerging Company Profile: The Phase III success of Pfizer's tafamidis means Eidos’ protein misfolding drug AG10 is not the first – but it is validated and differentiated, says BridgeBio-backed start-up Eidos.